ArticleCancer discovery2021
The Pediatric Precision Oncology INFORM Registry: Clinical Outcome and Benefit for Patients with Very High-Evidence Targets.
Open access · bronzeAbstract read
In one paragraph
Article in Cancer discovery, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 141 papers, 3 of them syntheses that pooled it.
0numbers the graph read from it
0cells of the map it votes in
141citing papers in PubMed, 3 pooled it
31.3field-weighted citation impact, top 1% of its field
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
141 citing papers in PubMed, 3 syntheses or guidelines pooled it, 242 citations in OpenAlex.
- Factors that influence the uptake of precision-guided treatment recommendations in paediatric cancer: a systematic review.British journal of cancer · 2026Pooled it
- Relapsed rhabdomyosarcoma: treatment recommendations from the European pediatric soft tissue sarcoma study group (EpSSG).British journal of cancer · 2025Guideline
- The prevalence and risk factors of anxiety in multiple sclerosis: A systematic review and meta-analysis.Frontiers in neuroscience · 2023Pooled it
- Phase I/II Study of the CDK2/9 Inhibitor Fadraciclib in Combination with Chemotherapy in Children with Advanced Malignancies: Arm K of the AcSé-ESMART Trial.Targeted oncology · 2026Trial
- Phase II Study of Samotolisib in Children and Young Adults With Tumors Harboring Phosphoinositide 3-Kinase/Mammalian Target of Rapamycin Pathway Alterations: Pediatric MATCH APEC1621D.JCO precision oncology · 2024Trial
- Olaparib for childhood tumors harboring defects in DNA damage repair genes: arm H of the NCI-COG Pediatric MATCH trial.The oncologist · 2024Trial
- Actionable Tumor Alterations and Treatment Protocol Enrollment of Pediatric and Young Adult Patients With Refractory Cancers in the National Cancer Institute-Children's Oncology Group Pediatric MATCH Trial.Journal of clinical oncology : official journal of the American Society of Clinical Oncology · 2022Trial
- A Practical Compass to Biological Digital Resources and Omics Integration in Ewing Sarcoma.Methods in molecular biology (Clifton, N.J.) · 2027Article
- Cytotoxic activity of selinexor in BRAFActa neuropathologica communications · 2026Article
- The ITCC-P4 PDX Platform Enables Preclinical Testing of Pediatric Cancers.Cancer research · 2026Article
- Genomic Medicine Sweden: Advancing precision medicine at the national level.Journal of internal medicine · 2026Review
- First-year results of the International Leukemia/ Lymphoma Target Board for pediatric relapsed and refractory hematological malignancies.Haematologica · 2026Article
- Interdisciplinary management and genetic evaluation of pediatric cancer predisposition syndromes: a retrospective cohort study.European journal of human genetics : EJHG · 2026Article
- High clinical utility of comprehensive multi-omic molecular profiling of rare and hard-to-diagnose pediatric tumors.Research square · 2026Article
- High clinical utility of comprehensive multi-omic molecular profiling of rare and hard-to-diagnose pediatric tumors.medRxiv : the preprint server for health sciences · 2026Article
- Circulating tumor DNA precision oncology enables effective and sensitive molecular diagnostics and actionable target detection in pediatric solid tumors - the INFORM experience.Genome medicine · 2026Article
- Impact of precision oncology research in pediatric poor prognosis cancer: patient, parent and healthcare provider perspectives.BMC cancer · 2026Article
- Integration and validation of complementary ex vivo assays for functional precision oncology.NPJ precision oncology · 2026Article
- Olive Leaf Extract Health-Promoting and Anti-Tumor Properties: An Adjunct Therapy in Pediatric Oncology?Nutrients · 2026Review
- Precision-guided therapy in H3K27-altered diffuse midline glioma.Nature communications · 2026Observational
81 more citing papers are in PubMed but not listed here.
Corrections and comments
- Commented on by
Authors and funding
74 authors at 20 institutions in 8 countries.
Cornelis M van Tilburg *Hopp Children's Cancer Center Heidelberg (KiTZ), Heidelberg, Germany. cornelis.vantilburg@kitz-heidelberg.de.ORCID 0000-0001-5274-910X
Elke Pfaff *Hopp Children's Cancer Center Heidelberg (KiTZ), Heidelberg, Germany.
Kristian W Pajtler *Hopp Children's Cancer Center Heidelberg (KiTZ), Heidelberg, Germany.
Karin P S Langenberg *Princess Máxima Center for Pediatric Oncology, Utrecht, the Netherlands.ORCID 0000-0002-6780-0585
Petra FieselGerman Cancer Consortium (DKTK), Heidelberg, Germany.
Barbara C JonesHopp Children's Cancer Center Heidelberg (KiTZ), Heidelberg, Germany.
Gnana Prakash BalasubramanianHopp Children's Cancer Center Heidelberg (KiTZ), Heidelberg, Germany.
Sebastian StarkHopp Children's Cancer Center Heidelberg (KiTZ), Heidelberg, Germany.
Pascal D JohannHopp Children's Cancer Center Heidelberg (KiTZ), Heidelberg, Germany.
Mirjam Blattner-JohnsonHopp Children's Cancer Center Heidelberg (KiTZ), Heidelberg, Germany.
Kathrin SchrammHopp Children's Cancer Center Heidelberg (KiTZ), Heidelberg, Germany.
Nicola DikowInstitute of Human Genetics, Heidelberg University Hospital, Heidelberg, Germany.
Steffen HirschHopp Children's Cancer Center Heidelberg (KiTZ), Heidelberg, Germany.ORCID 0000-0002-4920-0930
Christian SutterInstitute of Human Genetics, Heidelberg University Hospital, Heidelberg, Germany.
Kerstin GrundInstitute of Human Genetics, Heidelberg University Hospital, Heidelberg, Germany.
Arend von StackelbergGerman Cancer Consortium (DKTK), Heidelberg, Germany.
Andreas E KulozikHopp Children's Cancer Center Heidelberg (KiTZ), Heidelberg, Germany.
Andrej LissatGerman Cancer Consortium (DKTK), Heidelberg, Germany.
Arndt BorkhardtGerman Cancer Consortium (DKTK), Heidelberg, Germany.
Roland MeiselGerman Cancer Consortium (DKTK), Heidelberg, Germany.ORCID 0000-0001-5230-0628
Dirk ReinhardtGerman Cancer Consortium (DKTK), Heidelberg, Germany.
Jan-Henning KlusmannDepartment of Pediatric Hematology, Oncology and Hemostaseology, Clinic for Pediatrics, University Hospital of Frankfurt, Goethe-University Frankfurt, Frankfurt/Main, Germany.ORCID 0000-0002-1070-0727
Gudrun FleischhackGerman Cancer Consortium (DKTK), Heidelberg, Germany.ORCID 0000-0001-5714-007X
Stephan TippeltGerman Cancer Consortium (DKTK), Heidelberg, Germany.
Dietrich von SchweinitzGerman Cancer Consortium (DKTK), Heidelberg, Germany.
Irene SchmidDepartment of Pediatric Oncology and Hematology, Dr. von Hauner Children's Hospital, Ludwig-Maximilians-University Munich, Munich, Germany.
Christof M KrammDivision of Pediatric Hematology and Oncology, University Medical Center Göttingen, Göttingen, Germany.ORCID 0000-0002-5017-926X
André O von BuerenDepartment of Pediatrics, Obstetrics and Gynecology, Division of Pediatric Hematology and Oncology, University Hospital Geneva, Geneva, Switzerland.ORCID 0000-0003-4197-6264
Gabriele CalaminusDepartment of Pediatric Oncology and Hematology, University Hospital Bonn, Bonn, Germany.
Peter VorwerkDepartment of Pediatric Oncology and Hematology, University Hospital Magdeburg, Magdeburg, Germany.
Norbert GrafDepartment of Pediatric Oncology and Hematology, University Hospital Saarland, Saarland, Germany.ORCID 0000-0002-2248-323X
Frank WestermannGerman Cancer Consortium (DKTK), Heidelberg, Germany.
Matthias FischerNational Center for Tumor Diseases (NCT) Network, Germany.
Angelika EggertGerman Cancer Consortium (DKTK), Heidelberg, Germany.
Birgit BurkhardtClinic of Pediatric Oncology and Hematology, University Hospital Münster, Muenster, Germany.ORCID 0000-0002-1151-829X
Wilhelm WößmannDepartment of Pediatric Oncology and Hematology, University Hospital Hamburg, Hamburg, Germany.
Michaela NathrathGerman Cancer Consortium (DKTK), Heidelberg, Germany.
Stefanie Hecker-NoltingNational Center for Tumor Diseases (NCT) Network, Germany.
Michael C FrühwaldNational Center for Tumor Diseases (NCT) Network, Germany.
Dominik T SchneiderClinic of Pediatrics, Municipal Hospital Dortmund, Dortmund, Germany.ORCID 0000-0002-1810-0267
Ines B BrechtGerman Cancer Consortium (DKTK), Heidelberg, Germany.
Petra KettelerGerman Cancer Consortium (DKTK), Heidelberg, Germany.
Simone FuldaGerman Cancer Consortium (DKTK), Heidelberg, Germany.
Ewa KoscielniakNational Center for Tumor Diseases (NCT) Network, Germany.
Michael T MeisterGerman Cancer Consortium (DKTK), Heidelberg, Germany.ORCID 0000-0001-8311-721X
Monika ScheerGerman Cancer Consortium (DKTK), Heidelberg, Germany.
Simone HettmerGerman Cancer Consortium (DKTK), Heidelberg, Germany.ORCID 0000-0003-1709-4448
Matthias SchwabGerman Cancer Consortium (DKTK), Heidelberg, Germany.
Roman TremmelDr. Margarete Fischer-Bosch Institute of Clinical Pharmacology, Stuttgart, Germany.ORCID 0000-0003-1564-0433
Ingrid ØraDepartment of Pediatric Oncology and Hematology, Skane University Hospital Lund, and HOPE-ITCC Unit, Pediatric Oncology, Karolinska University Hospital, Stockholm, Sweden.ORCID 0000-0002-3931-4125
Caroline HutterSt. Anna Children's Hospital, Department of Pediatrics, Medical University of Vienna, and St. Anna Children's Cancer Research Institute (CCRI), Vienna, Austria.ORCID 0000-0003-2059-4814
Nicolas U GerberDepartment of Oncology, University Children's Hospital, Zurich, Switzerland.ORCID 0000-0002-1783-631X
Olli LohiTampere Center for Child Health Research and Tays Cancer Centre, Faculty of Medicine and Health Technology, Tampere University, Tampere, Finland.ORCID 0000-0001-9195-0797
Bernarda KazanowskaDepartment of Pediatric Hematology/Oncology and BMT, Wroclaw Medical University, Wroclaw, Poland.
Antonis KattamisDivision of Pediatric Hematology-Oncology, First Department of Pediatrics, National and Kapodistrian University of Athens, Athens, Greece.ORCID 0000-0002-5178-0655
Maria FilippidouHopp Children's Cancer Center Heidelberg (KiTZ), Heidelberg, Germany.
Bianca GoemansPrincess Máxima Center for Pediatric Oncology, Utrecht, the Netherlands.ORCID 0000-0003-4030-3228
C Michel ZwaanPrincess Máxima Center for Pediatric Oncology, Utrecht, the Netherlands.
Till MildeHopp Children's Cancer Center Heidelberg (KiTZ), Heidelberg, Germany.ORCID 0000-0002-7267-1052
Natalie JägerHopp Children's Cancer Center Heidelberg (KiTZ), Heidelberg, Germany.
Stephan WolfGerman Cancer Consortium (DKTK), Heidelberg, Germany.
David ReussGerman Cancer Consortium (DKTK), Heidelberg, Germany.
Felix SahmGerman Cancer Consortium (DKTK), Heidelberg, Germany.ORCID 0000-0001-5441-1962
Andreas von DeimlingGerman Cancer Consortium (DKTK), Heidelberg, Germany.
Uta DirksenGerman Cancer Consortium (DKTK), Heidelberg, Germany.ORCID 0000-0002-5435-7860
Angelika FreitagNCT Trial Center, National Center for Tumor Diseases, Heidelberg, Germany, and German Cancer Research Center (DKFZ), Heidelberg, Germany.
Ruth WittHopp Children's Cancer Center Heidelberg (KiTZ), Heidelberg, Germany.ORCID 0000-0002-3931-4125
Peter LichterGerman Cancer Consortium (DKTK), Heidelberg, Germany.
Annette Kopp-SchneiderGerman Cancer Consortium (DKTK), Heidelberg, Germany.ORCID 0000-0002-1810-0267
David T W JonesHopp Children's Cancer Center Heidelberg (KiTZ), Heidelberg, Germany.
Jan J Molenaar *Princess Máxima Center for Pediatric Oncology, Utrecht, the Netherlands.
David Capper *German Cancer Consortium (DKTK), Heidelberg, Germany.ORCID 0000-0003-1945-497X
Stefan M Pfister *Hopp Children's Cancer Center Heidelberg (KiTZ), Heidelberg, Germany.ORCID 0000-0002-5447-5322
Olaf Witt *Hopp Children's Cancer Center Heidelberg (KiTZ), Heidelberg, Germany.ORCID 0000-0002-3931-4125
German Cancer Research Center · DEHeidelberg University · DEPrincess Máxima Center · NLGoethe University Frankfurt · DENational Center for Tumor Diseases · DEDr. Margarete Fischer-Bosch-Institute of Clinical Pharmacology · DEKarolinska University Hospital · SEKlinikum Dortmund · DELudwig-Maximilians-Universität München · DENational and Kapodistrian University of Athens · GRSaarland University · DESt Anna Children's Hospital · ATTampere University of Applied Sciences · FIUniversität Hamburg · DEUniversitätsmedizin Göttingen · DEUniversity Children's Hospital Zurich · CHUniversity Hospital Augsburg · DEUniversity Hospital Bonn · DEUniversity Hospital Magdeburg · DEUniversity Hospital Münster · DE
Funding
No grant is acknowledged in the PubMed record.
Abstract
INFORM is a prospective, multinational registry gathering clinical and molecular data of relapsed, progressive, or high-risk pediatric patients with cancer. This report describes long-term follow-up of 519 patients in whom molecular alterations were evaluated according to a predefined seven-scale target prioritization algorithm. Mean turnaround time from sample receipt to report was 25.4 days. The highest target priority level was observed in 42 patients (8.1%). Of these, 20 patients received matched targeted treatment with a median progression-free survival of 204 days [95% confidence interval (CI), 99-not applicable], compared with 117 days (95% CI, 106-143;
Indexed as
NeoplasmsChildHumansPrecision MedicineProgression-Free SurvivalProspective StudiesRegistries
Identifiers
What OpenQuestion holds
Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390
Registered trials
None linked
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.